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differences from the clinical results
respectively obtained with NT-
proBNP and BNP assays, thus sug-
gesting that the performance of the
immunoassays used may a very cru-
cial point in determining the results
of a clinical study comparing differ-
ent CNH assays.
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Biological Variation of N-Terminal Pro-
Brain Natriuretic Peptide in Healthy
Individuals
To the Editor:
Brain natriuretic peptide (BNP) and
its N-terminal prohormone (NT-
proBNP) fragment have been shown
to be effective in diagnosing left ven-
tricular dysfunction (1, 2), and in
particular, they have a strong nega-
tive predictive value (3 ). NT-proBNP
and the hormone are secreted on an
equimolar basis, but NT-proBNP
lacks a clearance receptor. It there-
fore has a longer half-life in serum
than the active hormone does, and its
circulating concentration is believed
to be less influenced by the condi-
tions under which the blood sample
is taken.
Information on the biological vari-
ation of NT-proBNP is not available;
this is limiting because the clinical
utility of laboratory data can be af-
fected by physiologic variation (4 ).
Here we report the results of a study
to determine the biological variabil-
ity of NT-proBNP.
Five blood specimens were col-
lected from each of 16 apparently
healthy laboratory workers (5 men
and 11 women; age range, 43–62
years) twice a week (Tuesdays and
Fridays) over a 17-day period. None
of the workers smoked, took any
medication, or consumed substantial
quantities of alcohol. In accordance
with Helsinki Declaration II, the de-
sign and execution of the experiment
were explained thoroughly to the
participants, and informed consent
was obtained. Blood was collected
under standardized conditions to
minimize sources of preanalytic vari-
ation. After an overnight fast, a blood
specimen was taken by conventional
venipuncture between 0800 and 0900
with the volunteers in the sitting
position, avoiding venous stasis. All
samples were drawn by the same
phlebotomist, allowed to clot, and
then centrifuged at 3000g for 15 min
at room temperature within 1 h of
collection. Sera were separated and
stored at 70 °C until analysis. It has
been documented that the N-termi-
nal peptide can be safely stored fro-
zen at 20 and 80 °C for at least 3
months (5 ).
At the end of the collection period,
all frozen samples were thawed,
mixed, and centrifuged for analysis
in a single run in duplicate. NT-
proBNP concentrations were deter-
mined by an electrochemilumines-
cence sandwich immunoassay
(Roche Diagnostics). The assay was
performed on an Elecsys System
2010 by the same analyst, who fol-
lowed the assay manufacturer’s rec-
ommendations. After exclusion of
one outlier and logarithmic transfor-
mation of the data (required because
of the skewed distributions of the
NT-proBNP data), the analytical
(CVA) and intra- (CVI) and interindi-
vidual (CVG) components of varia-
tion were calculated by nested
ANOVA. We also calculated the crit-
ical difference for significant changes
in serial results (P 0.05), the index
of individuality, the number of spec-
imens required to estimate the ho-
meostatic setpoint of an individual
(within  10% with a confidence of
95%), and the desirable quality spec-
ifications for imprecision (I), bias (B),
and total error (TE), which were
calculated using the formulas: I 
0.5CVI; B  0.25 (CVI
2  CVG
2)1/2;
and TE  1.65 I  B ( 0.05). The
results are reported in Table 1.
Minor, not statistically significant
differences (P 0.87), were observed
between genders and were attribut-
Table 1. Mean values; estimated mean analytical (CVA), intraindividual (CVI),
and interindividual (CVG) variation; and derived indices for serum NT-proBNP.
Group
Mean,
pmol/L
CVA,
%
CVI,
%
CVG,
% IIa
Desirable quality specifications
CD, %
No. of
specimens
Imprecision,
%
Bias,
%
Total
error, %
All 8.37 2.7 9.1 14 0.64 4.6 4.22 11.72 26.33 3
Men 9.42 1.1 6.5 16 0.41 3.2 4.29 9.65 18.18 2
Women 7.98 3.1 10 14 0.71 5.0 4.32 12.57 29.04 4
a II, index of individuality; CD, critical difference.
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able to the lower CVI in the men. The
quality specifications for assay im-
precision (CVA  0.5CVI) were
widely fulfilled. The individuality in-
dex was close to 0.6, indicating that
an individual’s results are more use-
ful as reference values than are pop-
ulation-based data when the results
are used in monitoring. Finally, serial
results for pro-BNP must change by
26% before significance can be
claimed.
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PCR-based Detection of CYP21
Deletions
To the Editor:
We read with interest the Technical
Brief by Lee et al. (1 ), in which the
authors describe a novel method to
detect C4-CYP21 deletions in patients
with steroid 21-hydroxylase defi-
ciency. Such deletions result from an
unequal crossover in the RCCX mod-
ule (RP-C4-CYP21-TNX) on chromo-
some 6. In most cases, chromosome 6
carries two RCCX modules, one with
a CYP21P (CYP21A1P) pseudogene
and a truncated XA pseudogene, and
one with a functional CYP21
(CYP21A2) gene (encoding steroid
21-hydroxylase) and a functional
TNXB gene (encoding tenascin-X).
Meiotic misalignment and recombi-
nation may occur at several locations
and create a chromosome with a sin-
gle chimeric RCCX module. The PCR
described by Lee et al. uses one
primer in the 5 flanking sequence of
CYP21 and CYP21P (2), whereas the
other primer is positioned in a
120-bp sequence of TNXB that is not
present in the XA pseudogene (3 ).
Although this PCR is indeed suitable
for the detection of chimeric
CYP21P/CYP21 genes, it would fail
to detect any RCCX chimera in which
the pseudogene-like region includes
the 120-bp deletion of XA (4), as
illustrated in Fig. 1.
Lee et al. (1 ) successfully charac-
terized 18 patients by this method,
finding three categories of CYP21P/
CYP21 chimeras. Therefore, XA/
TNXB chimeras may be rare in the
Chinese population they studied. In
The Netherlands, however, such hy-
brids are common (5, 6): in our pa-
tient group, the PCR would have
yielded no product in four of nine
chimeric RCCX modules on bimodu-
lar chromosomes (6 ) as well as in a
recently described de novo deletion
(7 ). Thus, this method fails to detect
all CYP21 deletions.
To amend this problem, we recom-
mend that the TNXB-specific primer
be positioned beyond the RCCX du-
plication boundary, in the nondupli-
cated area of TNXB (see Fig. 1). This
will produce three additional TaqI
fragments, but these are smaller than
1 kb and should not interfere with
the agarose gel separation shown in
Fig. 1D of the Technical Brief by
Lee et al. (1 ). In addition, CYP21P/
CYP21 chimeras would then produce
a 2.5-kb TaqI fragment and could be
readily distinguished from XA/
TNXB chimeras, which would pro-
duce a 2.4-kb TaqI fragment.
Southern blotting remains the es-
tablished approach for comprehen-
sive analysis of this highly complex
and variable region of the human
genome. Genomic TaqI digestion
coupled with cohybridization with
CYP21, TNX, and C4 probes provides
direct information about these three
genes and alerts the investigator to
uncommon configurations that re-
quire further analysis by long-range
restriction mapping (8, 9). Although
we recognize the benefits of rapid
nonradioactive detection methods,
especially for diagnostic purposes,
careful evaluation of such methods is
necessary, notably if the method is
recommended for general use and
not limited to the population for
which it was originally designed.
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